Healthcare - Biotechnology - NASDAQ - GB
$ 1.05
-1.87 %
$ 43.1 M
Market Cap
-0.66
P/E
CASH FLOW STATEMENT
-48.4 M
OPERATING CASH FLOW
-1.1 M
INVESTING CASH FLOW
9 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Achilles Therapeutics plc
| Net Income | -69.9 M |
| Depreciation & Amortization | 4.71 M |
| Capital Expenditures | -1.1 M |
| Stock-Based Compensation | 6.36 M |
| Change in Working Capital | 10.4 M |
| Others | 10.4 M |
| Free Cash Flow | -49.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (69.9) | (71.2) | (61.1) | (33.2) | (14.0) | 6.89 K |
| Depreciation & Amortization | 4.7 | 3.7 | 3.3 | 0.8 | 0.3 | 173 |
| Deferred Income Tax | 0 | 0 | 0.2 | 0 | 14 K | 0 |
| Stock Based Compensation | 6.4 | 7.0 | 6.3 | 3.0 | 0.7 | 76 |
| Other Operating Activities | 7.03 K | 6.9 | 18 K | 1.2 | 9 K | 114 |
| Change in Working Capital | 10.4 | (6.0) | (7.9) | 3.0 | (1.2) | 846 |
| Cash From Operations | (48.4) | (59.5) | (59.3) | (25.3) | (14.1) | 7.6 K |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.1) | (7.5) | (7.6) | (11.8) | (0.9) | 258 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (1.1) | (7.5) | (7.6) | (11.8) | (0.9) | 258 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 160.8 | 113.7 | 93.2 | 13.5 K |
| Cash From Financing Activities | 9 K | 1 K | 0.2 | 113.7 | 93.6 | 13.5 K |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (41.8) | (93.0) | 88.5 | 80.3 | 86.9 | 5.7 K |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (49.5) | (67.0) | (66.9) | (37.1) | (15.1) | 7.86 K |